BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38047872)

  • 21. The importance of surgical staging in the treatment of malignant pleural mesothelioma.
    Rusch VW; Venkatraman E
    J Thorac Cardiovasc Surg; 1996 Apr; 111(4):815-25; discussion 825-6. PubMed ID: 8614142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes.
    Linton A; Soeberg M; Broome R; Kao S; van Zandwijk N
    Respirology; 2017 Jul; 22(5):978-985. PubMed ID: 28139858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.
    Friedberg JS; Simone CB; Culligan MJ; Barsky AR; Doucette A; McNulty S; Hahn SM; Alley E; Sterman DH; Glatstein E; Cengel KA
    Ann Thorac Surg; 2017 Mar; 103(3):912-919. PubMed ID: 27825687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality.
    Burt BM; Cameron RB; Mollberg NM; Kosinski AS; Schipper PH; Shrager JB; Vigneswaran WT
    J Thorac Cardiovasc Surg; 2014 Jul; 148(1):30-5. PubMed ID: 24726744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
    Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M
    Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
    Lococo F; Torricelli F; Lang-Lazdunski L; Veronesi G; Rena O; Paci M; Casadio C; Piana S; Novellis P; Di Stefano TS; Ciarrocchi A; Billè A
    J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1584-1593.e2. PubMed ID: 31590954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative prediction of unresectability in malignant pleural mesothelioma.
    Burt BM; Lee HS; Raghuram AC; Strange C; Mason J; Strange T; Delgado J; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2512-2520.e1. PubMed ID: 32087959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of Conversion to Extrapleural Pneumonectomy From Pleurectomy/Decortication for Malignant Pleural Mesothelioma.
    Nakamura A; Hashimoto M; Matsumoto S; Kondo N; Kijima T; Hasegawa S
    Semin Thorac Cardiovasc Surg; 2021; 33(3):873-881. PubMed ID: 33609685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma.
    Schwartz RM; Lieberman-Cribbin W; Wolf A; Flores RM; Taioli E
    BMC Cancer; 2018 Nov; 18(1):1188. PubMed ID: 30497433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
    Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
    Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma.
    Nelson DB; Rice DC; Niu J; Atay SM; Vaporciyan AA; Antonoff MB; Hofstetter WL; Walsh GL; Swisher SG; Roth JA; Tsao AS; Gomez DR; Giordano SH; Mehran RJ; Sepesi B
    Eur J Cardiothorac Surg; 2018 May; 53(5):960-966. PubMed ID: 29211849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.
    Beckett P; Edwards J; Fennell D; Hubbard R; Woolhouse I; Peake MD
    Lung Cancer; 2015 Jun; 88(3):344-8. PubMed ID: 25863904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
    Shaikh F; Zauderer MG; von Reibnitz D; Wu AJ; Yorke ED; Foster A; Shi W; Zhang Z; Adusumilli PS; Rosenzweig KE; Krug LM; Rusch VW; Rimner A
    J Thorac Oncol; 2017 Jun; 12(6):993-1000. PubMed ID: 28341225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of Malignant Pleural Mesothelioma in the Elderly Population.
    Verma V; Wegner RE; Ludmir EB; Hasan S; Colonias A; Grover S; Friedberg JS; Simone CB
    Ann Surg Oncol; 2019 Aug; 26(8):2357-2366. PubMed ID: 31011908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Outcomes With Recurrence After Pleurectomy/Decortication for Malignant Pleural Mesothelioma.
    Nakamura A; Takuwa T; Hashimoto M; Kuroda A; Nakamichi T; Matsumoto S; Kondo N; Kijima T; Yamakado K; Hasegawa S
    Ann Thorac Surg; 2020 May; 109(5):1537-1543. PubMed ID: 31962118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.
    Cao C; Tian DH; Pataky KA; Yan TD
    Lung Cancer; 2013 Sep; 81(3):319-327. PubMed ID: 23769317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
    Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
    Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma.
    Kostron A; Friess M; Crameri O; Inci I; Schneiter D; Hillinger S; Stahel R; Weder W; Opitz I
    Eur J Cardiothorac Surg; 2016 May; 49(5):1516-23. PubMed ID: 26590183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
    Opitz I; Bille A; Dafni U; Nackaerts K; Ampollini L; de Perrot M; Brcic L; Nadal E; Syrigos K; Gray SG; Aerts J; Curioni-Fontecedro A; Rüschoff JH; Monkhorst K; Weynand B; Silini EM; Bavaghar-Zaeimi F; Jakopovic M; Llatjos R; Tsimpoukis S; Finn SP; von der Thüsen J; Marti N; Dimopoulou G; Kammler R; Peters S; Stahel RA; Falcoz PE; Brunelli A; Baas P;
    J Thorac Oncol; 2023 Sep; 18(9):1233-1247. PubMed ID: 37356802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
    Frischknecht L; Meerang M; Soltermann A; Stahel R; Moch H; Seifert B; Weder W; Opitz I
    J Thorac Cardiovasc Surg; 2015 Jun; 149(6):1539-46.e1. PubMed ID: 25840756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.